We report a case of a 66-year-old severely osteoporotic woman with bisphosphonate-related osteonecrosis of the jaw (BRONJ) around her dental implants, who was treated successfully with teriparatide and sequestrectomy of the mandible. After 5 months of teriparatide therapy, the sequestrum separation had progressed and a sequestrectomy was performed under general anesthesia. Five months after the operation, new bone formation was observed around the bone defect in the region of the sequestrectomy. A repeat computed tomographic image revealed improvement in the bone defect in the mandible. These results suggest that teriparatide provides beneficial effects in the treatment of advanced BRONJ around dental implants.

Keywords: Bisphosphonate-related osteonecrosis of the jaw, Dental implant, Teriparatide

Background
Oral bisphosphonates (BPs) are used to treat osteoporosis, Paget’s disease, and osteogenesis imperfecta. They are most widely used for treatment of osteoporosis. BP-related osteonecrosis of the jaw (BRONJ) was first reported by Marx in 2003 [1]. The risk of BRONJ in osteoporotic patients treated with BPs remains low compared with that of oncology patients [2]. Recent studies have indicated that the relative incidence of BRONJ in patients with osteoporosis is higher than previously thought [3]. Madrid and Sanz [4] suggested that the placement of dental implants in patients treated with oral bisphosphonates was not associated with the onset of BRONJ; they found no relationship between the treatment and the survival of implants. However, more recently, an increasing number of peri-implant BRONJ cases have been described [5–9]. Peri-implant BRONJ currently is considered an additional complication related to oral implants, along with nerve injury, bleeding, sinus perforation, implant ingestion/aspiration, peri-implantitis, and mucositis [6].

We present a case of a severely osteoporotic woman with BRONJ around her dental implants, who was treated successfully with teriparatide and sequestrectomy.
healing abutments were connected. Provisional maxillary and left mandibular prostheses were cemented onto the abutments.

Nine months after the second surgery in June 2011, the patient started to complain of a painful cheek swelling on the right side of the mandible, associated with gingival bleeding. She was prescribed oral antibiotics by her dentist and underwent occasional antibiotic therapy thereafter.

In September 2011, the patient was referred to our clinic because her symptoms were getting worse. Clinical examination revealed an intraoral fistula on the lingual side of the dental implant replacing the right mandibular first molar, associated with mucosal inflammation and a purulent discharge (Fig. 1a, b). She also had hypoesthesia of the right lower lip. The patient underwent panoramic radiography (Fig. 2a) and computed tomography (CT), which showed bone resorption around the dental implant in the right mandibular first molar area and severe peri-implantitis in the right mandibular molar region. There was no obvious sequestrum separation (Fig. 2b, c). Under a clinical diagnosis of perimandibular inflammation and peri-implantitis, conservative treatment consisting of local irrigation and use of antibiotics was implemented. Meropenem hydrate was given initially, then changed to ampicillin/sulbactam. The inflammatory state improved, and when the symptoms subsided, treatment with clarithromycin was continued. Debridement and removal of the dental implant in the right mandibular first molar area was performed under local anesthesia. Irrigation of the site was continued as part of the treatment regimen.

In November 2011, after a consultation with an osteoporosis expert at the Orthopedic Medicine Clinic of our hospital, alendronate therapy was stopped and subcutaneous teriparatide therapy at a dose of 20 μg per day was started. During the course of the teriparatide therapy, the patient continued to use 0.02% benzalkonium chloride solution for local irrigation.

In April 2012, after 5 months of teriparatide therapy, the sequestrum separation had progressed (Fig. 3), and a sequestrectomy was performed under general anesthesia (Fig. 4). At 5 months after the operation, a CT scan revealed new bone formation around the bone defect in the region of the sequestrectomy, with all symptoms including bone exposure disappearing (Fig. 5). The patient’s osteoporosis treatment was continued, and 16 months after the sequestrectomy, further new bone formation was observed (Fig. 6).

Discussion

We describe a case of a patient with a 6-year history of alendronate therapy, in which BRONJ developed around her dental implants. In this patient, the dental implants achieved successful osseointegration, and BRONJ occurred after the second surgery. Several factors could have played a role in the development of BRONJ in this patient. Glucocorticoid therapy is associated with an increased risk of BRONJ. This may be a result of multiple factors including inhibition of osteoblast function and increased osteoblast and osteocyte apoptosis. Other effects of glucocorticoids that may contribute to an increased risk of BRONJ include increased bone resorption, immunosuppression, impaired wound healing, and increased risk of local infection [10]. Patient-related local risk factors include dentoalveolar surgery (e.g., tooth extraction) and pre-existing inflammatory dental disease, such as periodontal disease or periapical pathology [11]. Although BPs tend to accumulate in sites of active bone remodeling, such as the jaws, the surgical trauma to the alveolar bone during implant surgery could have further stimulated the postoperative accumulation of the drug in the implant site. The localized interference of BPs on bone turnover may have influenced the peri-implant bone resistance to oral bacteria in the long term, thus increasing the risk of peri-implantitis. Once infection of the implanted bone site is established, BPs further accumulate because of the increased bone turnover; the onsite activation of bisphosphonates will hamper the healing capacity of bone, leading to bone necrosis and sequestration [5].

Nevertheless, the role of the dental implant procedure as a BRONJ pathogenetic factor [12–15] is still unclear.

Fig. 1 a Extraoral photograph showing an extraoral fistula in the right mandibular region. b Intraoral photograph showing an intraoral fistula on the lingual side of the distal dental implants associated with mucosal inflammation and a purulent discharge.
Fig. 2  
(a) Panoramic radiograph showing marked alveolar bone resorption surrounding the dental implant replacing the right mandibular first molar (arrow).  
(b) Sagittal CT view.  
(c) Coronal CT view.

Fig. 3  
(a) Panoramic radiograph showing the sequestrum separation after 5 months of teriparatide therapy (arrows).  
(b) Sagittal CT view.  
(c) Coronal CT view.
Recently, an increasing number of peri-implant BRONJs have been described [5–9]. Peri-implant BRONJ has been classified into two types: implant surgery-triggered BRONJ, when it develops within 6 months after implant surgery, suggesting that the surgical process may be a contributing factor; and non-implant surgery-triggered BRONJ, if it develops 6 months or more after implant surgery, or when BP administration started after implant placement and osteointegration [8]. Most authors do not consider the surgical procedure of implantation as a trigger factor for MRONJ [7, 8, 14, 16–20].

It is therefore important that all patients treated with oral BPs must be given a full explanation of the potential risks of implant failure and BRONJ development in the short and long term. Because the potential role of infection in implant failure and BRONJ occurrence is still debated, great attention should be paid to the long-term oral hygiene and plaque control of implant-prosthetic restorations in patients taking oral BPs.

BPs and other antiresorptives such as denosumab increase apoptosis and inhibit osteoclast differentiation and function, all leading to decreased bone resorption and remodeling [11]. Teriparatide may counteract these mechanisms by stimulating bone remodeling. It has been shown to stimulate the activity and viability of osteoblasts from the alveolar bone of chronic bisphosphonate users [21], while indirectly increasing the metabolic activity and number of osteoclasts by affecting osteoblast function [22]. An increased number of remodeling units and increased bone formation within each unit may promote healing and the removal of damaged bone. Thus, teriparatide may offer therapeutic promise for localized bone defects of the jaw in patients with BRONJ [3, 23–25].

While it has been suggested recently that assertive surgical removal of the sequestrum appears to be effective [26–29], it can sometimes be difficult to distinguish living bone from necrotic bone. Recently, resection of BRONJ-affected tissue produced healing in patients taking oral bisphosphonates more successfully than conservative management [30]. However, bone resection
because of surgical treatment may lead to significant oral disability.

Activation of living bone turnover by teriparatide therapy causes progression of the separation of the sequestrum. As a result, teriparatide therapy promotes sequestrum separation followed by normal mucosal coverage of the exposed bone. After 5 months of teriparatide therapy in our patient, sequestrum separation had progressed and thus a sequestrectomy was performed under general anesthesia. After the wound in the affected area had healed, our patient did not report any problems pertaining to her ability to ingest food, despite the presence of the bone defect in the mandible. We treated the patient with teriparatide for 2 years. CT monitoring of the mandible would assist in determining whether teriparatide can allow complete recovery of the bone defect in the mandible in cases of ONJ induced by bisphosphonates.

Conclusions
We have reported a case of a severely osteoporotic elderly woman with BRONJ around her dental implants, who was treated successfully with teriparatide. Teriparatide therapy appeared to exert beneficial effects in this patient.

Funding
This report was supported by Grant-in-Aid for Researchers, Hyogo College of Medicine, 2016.

Authors’ contributions
YZ and KT participated in the design of the study and drafted of the manuscript. JT and MU participated in the acquisition of data. YZ and HK participated in surgical treatment. KN and HK participated in the manuscript review. All authors read and approved the final manuscript.

Authors’ information
YZ is a specialist in Oral and Maxillofacial Surgery and a research student of the Department of Oral and Maxillofacial Surgery. KT and KN are associate professors of the Department of Oral and Maxillofacial Surgery. JT is a graduate student of the Department of Oral and Maxillofacial Surgery. MU is a senior resident of the Department of Oral and Maxillofacial Surgery. HK is a professor and chief of the Department of Oral and Maxillofacial Surgery.

Competing interests
Yusuke Zushi, Kazuki Takaoka, Joji Tamaoka, Miho Ueta, Kazuma Noguchi, and Hiromitsu Kishimoto declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Received: 6 December 2016 Accepted: 12 February 2017
Published online: 30 March 2017

References
1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.
2. Marx RE, Sawatari J, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567.
3. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone (rPTh(1-34)). J Oral Maxillofac Surg. 2007;65:573–80.
4. Madrid C, Sanz M. What influence do anticoagulants have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009;20(Suppl4):96–106.
5. Bedogni A, Bettini G, Totola A, et al. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg. 2010;68:1662–6.
6. Favia G, Piattelli A, Sportelli P, et al. Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res. 2011;13:58–63.
7. Lazarovic I, Yahalom R, Tacher S, et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg. 2010;68:790–6.
8. Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2014;25:632–40.

Fig. 6 a Panoramic radiograph 16 months after the sequestrectomy. b Sagittal CT view. c Coronal CT view d 3D CT view
9. Jacobsen C, Metzler P, Rössle M, et al. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig. 2013;17:167–75.

10. Saad F, Brown JE, Van PC, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.

11. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2015;73:1440.

12. Koka S, Babu NMS, Norell A. Survival of dental implants in post-menopausal bisphosphonate users. J Prosthodont Res. 2010;54:106–11.

13. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg. 2008;66:1022–4.

14. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008;66:223–30.

15. Goiss A, Bartold M, Sambrook P, Hawker P. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg. 2010;68:337–43.

16. Holzinger D, Seemann R, Matoni N, et al. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 1937;2014(72):e1–8.

17. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009;20 Suppl 4:496–106.

18. Matsuo A, Hamada H, Takahashi H, et al. Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients. Odontology. 2016;104:363–71.

19. Vescovi P, Campisi G, Fusco V, et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011;47:191–4.

20. Walter C, Al-Nawas B, Wolff T, et al. Dental implants in patients treated with antiresorptive medication: a systematic literature review. Int J Implant Dent. 2016;2:9.

21. Rao MV, Berk J, Almojaly SA, et al. Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy. Int J Mol Med. 2009;23:407–13.

22. Charles JF, Aliprantis AO. Osteoclasts: more than ‘bone eaters’. Trends Mol Med. 2014;20:499–509.

23. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009;36:1835–7.

24. Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med. 2010;363:2473–4.

25. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010;363:2396–405.

26. Abu-Id MH, Wannke PH, Gottschalk J, et al. “Bis-phossy jaws”—high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2008;36:95–103.

27. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg. 2009;67:943–50.

28. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67:85–95.

29. Wilde F, Heufelder M, Winter K, et al. The role of surgical therapy in the management of intravenous bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:153–63.

30. Silva LF, Curra C, Munerato MS, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. Oral Maxillofac Surg. 2016;20:9–17.